Investors
EMERGIA Inc.
Welcome to the Investor Relations Section of the EMERGIA website. As an investor or potential investor in EMERGIA, you should know that the Company is committed to provide a high standard of corporate disclosure and to leading corporate governance practices.
To learn more about the Company and its strategy, please review the information on this website or by talking to one of the members of the Company’s Executive team.
For a complete listing information, please visit EMERGIA’s quotation page at CSE:EMER
Stock Quote
CSE:EMER
EMERGIA Inc. – Public company News Releases:
- EMERGIA ANNOUNCES REPAYMENT OF DEBT THROUGH JOINT VENTURES AND EXTENSION OF ITS CURRENT PRIVATE PLACEMENT OFFERING November 11, 2020
- EMERGIA INC. ANNOUNCES FIRST CLOSING OF ITS PRIVATE PLACEMENT OF UNITS AND RELATED DEBT SETTLEMENT AND WELCOMES THE ARRIVAL OF A NEW DIRECTOR ON THE BOARD July 16, 2020
- EMERGIA INC. POSTPONES FILING OF INTERIM FINANCIAL STATEMENTS AND MD&A DUE TO COVID-19 RELATED DELAYS AND PROVIDES UPDATE REGARDING RELEASE OF ANNUAL FINANCIAL STATEMENTS AND MD&A June 2, 2020
- EMERGIA INC. INTENDS TO RELY ON THE EXEMPTION ALLOWING THE EXTENSION OF THE DATE OF FILING OF THE FINANCIAL STATEMENTS DUE TO COVID-19 April 20, 2020
- EMERGIA INC. PROVIDES UPDATE ON COVID-19 AND EXTENSION OF ITS PRIVATE PLACEMENT April 7, 2020
Shareholders
Information:
Financial Reports
The following continuous disclosure reports are available in PDF format. To view these reports, you will need Adobe® Acrobat® Reader™ which is available for free download from the Adobe Web site.
- 2021 Q1 March 31 – Financial Statements
- 2021 Q1 March 31 – MD&A
- 2020 Q4 December 31 – Audited Financial Statements
- 2020 Q4 December 31 – MD&A
- 2020 Q3 September 30 – Financial Statements
- 2020 Q3 September 30 – MD&A
- 2020 Q2 June 30 – Financial Statements
- 2020 Q2 June 30 – MD&A
- 2020 Q1 March 31 – Financial Statements
- 2020 Q1 March 31 – MD&A
- 2019 Q4 December 31 – Audited Financial Statements
- 2019 Q4 December 31 – MD&A
- 2019 Q3 September 30 – Financial Statements
- 2019 Q3 September 30 – MD&A
- 2019 Q2 June 30 – Financial Statements
- 2019 Q2 June 30 – MD&A
- 2019 Q1 March 31 – Financial Statements
- 2019 Q1 March 31 – MD&A
- 2018 Q4 December 31 – Audited Financial Statements
- 2018 Q4 December 31 – MD&A (Amended)
- 2018 Q3 September 30 – Financial Statements
- 2018 Q3 September 30 – MD&A
- 2018 Q2 June 30 – Financial Statements
- 2018 Q2 June 30 – MD&A
- 2018 Q1 March 31 – Financial Statements
- 2018 Q1 March 31 – MD&A
- 2017 Annual Financial Statements & MD&A
Transfer Agent, Registrar & Auditors
Transfer Agent and Registrar
TSX Trust
301-100 Adelaide Street West
Toronto ON M5H 4H1
Toll Free: 1 866 393-4891
T: 416 361-0930
F: 416 361-0470
Investor Inquiries: TMXEInvestorServices@tmx.com
Auditors
Raymond Chabot Grant Thornton
National Bank Tower
Suite 2000, 600 de la Gauchetiere Street West
Montreal, QC H3B 4L8
Share Structure
Share Capital Issued & Outstanding:
| Class A common shares | 10,107,730 | |
| Class B common shares | 4,510,890 | |
| Total Shares Outstanding | 14,618,620 |
Proxy Circular
The following continuous disclosure reports are available in PDF format.
